Synaptic phosphorylated a-synuclein in dementia with Lewy bodies

Dementia with Lewy bodies is characterized by the accumulation of Lewy bodies and Lewy neurites in the CNS, both of which are composed mainly of aggregated a-synuclein phosphorylated at Ser129. Although phosphorylated a-synuclein is believed to exert toxic effects at the synapse in dementia with Lewy bodies and other a-synucleinopathies, direct evidence for the precise synaptic localization has been difficult to achieve due to the lack of adequate optical microscopic resolution to study human synapses. In the present study we applied array tomography, a microscopy technique that combines ultrathin sectioning of tissue with immunofluorescence allowing precise identification of small structures, to quantitatively investigate the synaptic phosphorylated a-synuclein pathology in dementia with Lewy bodies. We performed array tomography on human brain samples from five patients with dementia with Lewy bodies, five patients with Alzheimer’s disease and five healthy control subjects to analyse the presence of phosphorylated a-synuclein immunoreactivity at the synapse and their relationship with synapse size. Main analyses were performed in blocks from cingulate cortex and confirmed in blocks from the striatum of cases with dementia with Lewy bodies. A total of 1 318 700 single pre- or post-synaptic terminals were analysed. We found that phosphorylated a-synuclein is present exclusively in dementia with Lewy bodies cases, where it can be identified in the form of Lewy bodies, Lewy neurites and small aggregates (50.16 mm3). Between 19% and 25% of phosphorylated a-synuclein deposits were found in presynaptic terminals mainly in the form of small aggregates. Synaptic terminals that co-localized with small aggregates of phosphorylated a-synuclein were significantly larger than those that did not. Finally, a gradient of phosphorylated a-synuclein aggregation in synapses (pre4pre + post4post-synaptic) was observed. These results indicate that phosphorylated a-synuclein is found at the presynaptic terminals of dementia with Lewy bodies cases mainly in the form of small phosphorylated a-synuclein aggregates that are associated with changes in synaptic morphology. Overall, our data support the notion that pathological phosphorylated a-synuclein may disrupt the structure and function of the synapse in dementia with Lewy bodies.

[1]  D. Clayton,et al.  Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.

[2]  E. Masliah,et al.  A Pathologic Cascade Leading to Synaptic Dysfunction in α-Synuclein-Induced Neurodegeneration , 2010, The Journal of Neuroscience.

[3]  Steven Hou,et al.  Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. , 2012, Brain : a journal of neurology.

[4]  A. Rosso,et al.  Neuritic Pathology as a Correlate of Synaptic Loss in Dementia With Lewy Bodies , 2008, American journal of Alzheimer's disease and other dementias.

[5]  W. Honer,et al.  Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease , 1994, Brain Research.

[6]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[7]  Anders Björklund,et al.  TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity , 2013, Proceedings of the National Academy of Sciences.

[8]  L. Wilkins,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium , 2005 .

[9]  I. Ferrer,et al.  Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies , 2001, Journal of Neural Transmission.

[10]  T. Hortobágyi,et al.  Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia , 2016, Alzheimer's & Dementia.

[11]  Alan J. Thomas,et al.  Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations , 2016, Acta neuropathologica communications.

[12]  A. Recasens,et al.  Alpha-synuclein spreading in Parkinson’s disease , 2014, Front. Neuroanat..

[13]  Stephen W. Scheff,et al.  Quantitative assessment of cortical synaptic density in Alzheimer's disease , 1990, Neurobiology of Aging.

[14]  K. Gamble,et al.  Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes , 2014, Molecular biology of the cell.

[15]  Rosemary J. Jackson,et al.  Human tau increases amyloid β plaque size but not amyloid β‐mediated synapse loss in a novel mouse model of Alzheimer's disease , 2016, The European journal of neuroscience.

[16]  M. Wegrzynowicz,et al.  Synaptic failure and α‐synuclein , 2016, Movement disorders : official journal of the Movement Disorder Society.

[17]  Michael L. Kramer,et al.  Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies , 2007, The Journal of Neuroscience.

[18]  Alan J. Thomas,et al.  Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment , 2014, Neurobiology of Aging.

[19]  Michael Alford,et al.  Differing patterns of aberrant neuronal sprouting in Alzheimer's disease with and without Lewy bodies , 1993, Brain Research.

[20]  D. Aarsland,et al.  Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias , 2016, Molecular Brain.

[21]  B. Boeve,et al.  Lewy body dementias , 2015, The Lancet.

[22]  B. Ghetti,et al.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. , 2010, Brain : a journal of neurology.

[23]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[24]  W. Honer,et al.  Synaptic Proteins and Choline Acetyltransferase Loss in Visual Cortex in Dementia With Lewy Bodies , 2013, Journal of neuropathology and experimental neurology.

[25]  C. Meshul,et al.  Presynaptic Alpha-Synuclein Aggregation in a Mouse Model of Parkinson's Disease , 2014, The Journal of Neuroscience.

[26]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[27]  C. Masters,et al.  Accumulation of Insoluble α-Synuclein in Dementia with Lewy Bodies , 2000, Neurobiology of Disease.

[28]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[29]  E. Masliah,et al.  The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.

[30]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  T. Spires-Jones,et al.  Synaptic pathology: A shared mechanism in neurological disease , 2016, Ageing Research Reviews.

[32]  Alan J. Thomas,et al.  Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia , 2014, F1000Research.

[33]  Stephen J. Smith,et al.  Deep molecular diversity of mammalian synapses: why it matters and how to measure it , 2012, Nature Reviews Neuroscience.

[34]  David Artigas,et al.  STED imaging performance estimation by means of Fourier transform analysis. , 2017, Biomedical optics express.

[35]  J. Trojanowski,et al.  Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.

[36]  Michael Unser,et al.  A pyramid approach to subpixel registration based on intensity , 1998, IEEE Trans. Image Process..

[37]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[38]  B. Hyman,et al.  Studying synapses in human brain with array tomography and electron microscopy , 2013, Nature Protocols.

[39]  L. Thal,et al.  Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer’s disease , 2000, Neurobiology of Aging.

[40]  W. Schulz-Schaeffer.  The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.

[41]  S. Love,et al.  Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer’s disease and dementia , 1998, Journal of neurology, neurosurgery, and psychiatry.

[42]  E. Bigio,et al.  Neocortical Synapse Density and Braak Stage in the Lewy Body Variant of Alzheimer Disease: A Comparison with Classic Alzheimer Disease and Normal Aging , 1998, Journal of neuropathology and experimental neurology.

[43]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[44]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[45]  B. Hyman,et al.  Dementia with Lewy Bodies , 1998, Journal of the American Geriatrics Society.

[46]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[47]  G. Muntané,et al.  Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related α-synucleinopathies , 2008, Neuroscience.

[48]  Masato Hasegawa,et al.  Prion-like spreading of pathological α-synuclein in brain , 2013, Brain : a journal of neurology.

[49]  Ole Isacson,et al.  Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy , 2009, The Journal of Neuroscience.

[50]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[51]  A. Kakita,et al.  Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice , 2010, Acta Neuropathologica.

[52]  J. Power,et al.  Neuronal response in Alzheimer’s and Parkinson’s disease: the effect of toxic proteins on intracellular pathways , 2015, BMC Neuroscience.

[53]  Stephen J. Smith,et al.  Array Tomography: A New Tool for Imaging the Molecular Architecture and Ultrastructure of Neural Circuits , 2007, Neuron.

[54]  H. Shill,et al.  Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains , 2013, Experimental Neurology.

[55]  Kristina D. Micheva,et al.  Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques , 2009, Proceedings of the National Academy of Sciences.

[56]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[57]  James W Ironside,et al.  Brain banking for neurological disorders , 2013, The Lancet Neurology.

[58]  T. Iwatsubo,et al.  Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain , 2003 .

[59]  D. Price,et al.  Synapse loss in the temporal lobe in Alzheimer's disease , 1993, Annals of neurology.